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Abstract
Background: In mammals, the IGF-1 pathway affects the phenotype of aging. Since the function of the immune
system is modulated by IGF-1, it is plausible that immunosenescence might in part result from altered control by
this pathway. We therefore examined whether the expression of IGF-1R, FOXO1, and FOXO3a in peripheral blood
mononuclear cells (PBMC) changes with age and if this might be due to changes in the expression of select
miRNAs.
Methods: The expression of IGF-1R, FOXO1, FOXO3a, as well as of miR-9, miR-96, miR-99a, miR-132, miR-145, and
miR-182 was examined in PBMC of young (27.8 ± 3.7 years), elderly (65.6 ± 3.4 years), and long-lived (94.0 ± 3.
7 years) Polish Caucasians using real-time PCR. mRNA/miRNA interactions were studied in HEK 293 cells using
luciferase-expressing pmirGLO reporter vector.
Results: The median expression of IGF-1R decreased with age (p < 0.000001), as did the expression of FOXO1 (p < 0.
000001), while the expression of FOXO3a remained stable. We also found an age-associated increase of the median
expression of miR-96 (p = 0.002), miR-145 (p = 0.024) and miR-9 (p = 0.026), decrease of the expression of miR-99a (p
= 0.037), and no changes regarding miR-132 and miR-182. Functional studies revealed that miR-96 and miR-182
interacted with human IGF-1R mRNA, and that miR-145 and miR-132 interacted with human FOXO1 mRNA.
Conclusions: The age-associated higher expression of miR-96 and miR-145 might contribute to the lower
expression of IGF-1R while the higher expression of miR-96, miR-145 and miR-9 might contribute to the lower
expression of FOXO1 in peripheral blood mononuclear cells of aging humans. Sustained expression/function of
FOXO3a but not of the other two genes might be important for the maintenance of the immune system function
in these individuals.
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Background
Aging is a multifactorial process affecting all tissues and
organs, which depends on genetic, epigenetic, environ-
mental and stochastic factors. On the molecular level,
one of its key features is aging-associated change of gene
activity, to a large extent driven by epigenetic drift, a
subtle but progressive change of the epigenome, charac-
terized by global DNA demethylation, hypermethylation
of select promoters, histone code alterations and change
in miRNAs expression [1–3]. miRNAs are short, non-
coding, single-stranded RNA molecules that regulate
gene expression at the pre-translational level [4]. Not-
ably, aging-associated change of miRNA expression and
its phenotypic effects are not completely elucidated,
mostly due to the complex nature of miRNA action and
to the fact that miRNA expression changes seems to be,
at least in part, tissue-specific [5–7].
The first indications of an involvement of the insulin/
IGF-1 pathway in the regulation of lifespan originated
from experiments performed on Caenorhabditis elegans,
in which mutations reducing the activity of daf-2, an
ortholog of mammalian IGF-1 and insulin receptors
(IGF-1R and IR, respectively), significantly extended the
lifespan of this nematode [8]. The effect has been shown
to be mediated by daf-16, an ortholog of mammalian
forkhead transcription factors (FOXO). Stimulation of
IGF-1R leads to Akt-dependent phosphorylation of
FOXO, its sequestration in the cytoplasm, and to inhib-
ition of its longevity-promoting activity [9, 10],while
overexpression of FOXO increases the duration of life
[11, 12]. Involvement of this pathway in longevity con-
trol was further confirmed in Drosophila melanogaster
[13, 14]. In mice, heterozygous deletion of IGF-1R (null
animals were not viable) resulted in lifespan extension
by 33% in females [15], however, this was not replicated
by other authors [16]. In humans, genetic variants of
FOXO3A were quite consistently reported as associated
with longevity [17–19]. In contrast, only a few scientific
reports described an association of the IGF-1R and
FOXO1 variants with longevity [18, 20], while others did
not see such associations [21, 22]. Therefore, the effect
of IGF-1 pathway on longevity in mammals in general
and in humans in particular, remains a controversial
issue. Nonetheless, it is well established that modifica-
tions of this pathway significantly affect the phenotype
of aging, as age-related decrease in circulating IGF-1
levels contributes to the development of cardiovascular
disease, stroke, type 2 diabetes mellitus, osteoporosis,
sarcopenia, and frailty but, at the same time, lowers the
risk of cancer [23–28].
An integral part of aging is immunosenescence. Its
most important features are: a decreased number of
naïve T and B lymphocytes, an increased number of
memory and effector T and B lymphocytes as well as of
natural killer cells the function of which is altered, an
impaired production of interleukins and cytokines, an
overproduction of autoantibodies and production of less
effective antibodies, all leading to a low-grade chronic
inflammation, a decreased response to pathogens and to
immunization, and to the increased risk of autoimmun-
ity and cancers [29]. The function of the immune system
depends on numerous factors and pathways, including
the growth hormone/IGF-1 pathway [30, 31], the func-
tion of which also varies with age, being one of the
hypothetical causes of immunosenescence. Indeed, a
significant correlation has been demonstrated between
plasma IGF-1 levels and the T lymphocyte (but not B-
lymphocyte) proliferative response in young and elderly
humans [32]. Furthermore, in aged female rhesus mon-
keys, administration of recombinant human IGF-1
resulted in an increased percentage of circulating B lym-
phocytes and of CD8 cells as well as of antibody produc-
tion to tetanus toxoid [33].
The biological effects of IGF-1 depend not only on the
concentration of this factor, but also on the expression
and activity of its receptor and of other proteins, that
form the IGF-1 pathway. Therefore, the main objective
of our work was to establish whether the expression of
major components of the IGF-1 axis, IGF-1R, FOXO1
and FOXO3a, changes with age in human peripheral
blood mononuclear cells (PBMC). Our second objective
was to establish whether an altered expression of the se-
lected miRNAs might contribute to IGF-1R, FOXO1 and
FOXO3a age-associated expression differences.
Methods
Study subjects
Polish Caucasians were divided into the young (Y, n =
56, age range 20–39 years, mean age 27.8 ± 3.7 years, 29
females, 27 males), elderly (E, n = 52, 60–73 years, 65.4
± 3.4 years, 25 females, 27 males), and long-lived (L, n =
48, 90–102 years, 94.2 ± 3.7 years, 31 females, 17 males)
age groups (Table 1). They were non-obese, without
signs and symptoms of current infection, and without
history of myocardial infarction, stroke, type 2 diabetes
mellitus, cancer, or neurodegeneration. However, in the
E and L groups moderate hypertension was allowed, and
some study participants belonging to the L group had a
mild degree physical or cognitive disability. Physical
performance and cognitive functioning were assessed
during recruitment for the study with the Activities of
Daily Living (ADL) scale [34] and Mini-Mental State
Examination (MMSE) [35], respectively. The following
cut-offs were used for physical performance: ADL score
5–6 – independent, 3–4 – partially dependent, 0–2 – to-
tally dependent, and for cognitive functioning: MMSE
score 28–30 – normal cognition, 24–27 – minimal cog-
nitive impairment, 20–23 – mild, 10–19 – moderate,
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<10 – severe cognitive impairment. Fifteen percent of
elderly and 41% of long-lived individuals were taking
low-dose acetylsalicylic acid. All participants gave a writ-
ten informed consent for participation in the study. The
anonymity of patients has been preserved at all stages of
this investigation. The study protocol was approved by
the Bioethics Committee of the Medical University of
Warsaw.
Isolation of PBMC and isolation of RNA
Human peripheral blood mononuclear cells were iso-
lated as previously described [36]. Next, since the avail-
able data indicated that TRIzol (Invitrogen, Carlsbad,
CA, USA) is suitable for isolation of both long and short
RNAs and their further analysis using RT-PCR, next
generation sequencing, etc., and that it is not inferior to
other isolation methods [37–41], we used this reagent to
isolate total RNA according to the procedure supplied
by the manufacturer. The integrity of RNA was assessed
using Agilent 2100 Bioanalyzer (Agilent, CA, USA).
Reverse transcription
To obtain cDNA for analysis of gene expression, the re-
actions were performed with 100 ng of PBMC total
RNA and with random hexamers using the RevertAidTM
H Minus First Strand cDNA Synthesis Kit (Thermo Sci-
entific, Vilnius, Lithuania). For analysis of miRNA
expression, reverse transcriptions were performed with
100 ng of total RNA and with a poly-T primer with a 3’
degenerate anchor and a 5’ universal tag from the miR-
CURY LNA™ Universal RT microRNA PCR system kit
(EXIQON, Vedbaek, Denmark).
Real-time quantification of gene expression and of miRNA
expression
The expression of IGF-1R, FOXO1 and of FOXO3 was
analyzed with semi-quantitative real-time PCR using the
LightCycler 480 SYBR Green I Master kit (Roche Diag-
nostic, Mannheim, Germany) in the Light Cycler 480
(Roche Diagnostic, Mannheim, Germany). The primers
for IGF-1R were: forward 5’TGAAAGTGACGTCCTGC
ATTTC3’ and reverse 5’GGTACCGGTGCCAGGTT
ATG3’, for FOXO1: forward 5’TGGACATGCTCAGCAG
ACATC3’ and reverse 5’TTGGGTCAGGCGGTTCA3’,
and for FOXO3a: forward 5’GAACGTGGGGAACTT-
CACTGGTGCTA3’ and reverse 5’GGTCTGCTTTGC
CCACTTCCCCTT3’. The reaction was carried out as
follows: 5 min at 95 °C, 45 cycles of 12 s at 95 °C, 12 s
at 60 °C and 12 s at 72 °C, followed by a melting curve
cycle. The results were normalized against the expres-
sion of the ACTB gene. Each reaction was performed in
duplicate.
To evaluate the expression of miRNAs, a real-time
PCR was performed with the miRCURY LNA™ Universal
RT microRNA PCR system and SYBR Green kits (EXI-
QON, Vedbaek, Denmark) in the Light Cycler 480,
according to the manufacturer’s protocol. The reaction
conditions were: 10 min at 95 °C, 50 cycles of 10 s at
95 °C, 1 min at 60 °C, followed by melting curve cycle.
The results were normalized against the expression of
endogenous control U6 snRNA. Each reaction was per-
formed in duplicate.
Functional analysis of miRNA
Candidate miRNAs were searched for using in silico
analysis with the TargetScanHuman [42], miRanda-
mirSVR [43] and the Pictar [44] programs. Using this
approach, we selected miR-96, miR-99a, miR-145, and
miR-182 for IGF-1R mRNA, and miR-9, miR-96, miR-
132, miR-145, and miR-182 for FOXO1 mRNA.
DNA corresponding to the 5’ end (721 bp) of 3’UTR
of IGF-1R mRNA was amplified with Dream Taq poly-
merase (Thero Scientific, Vilnius, Lithuania) with for-
ward 5’ACTAGAGCTCGACCTGCTGATCCTTGG3’
(added SacI restriction site shown in bold, the STOP
codon is underlined) and reverse 5’TAAGCTCGAG
AGCTGTCTCTCAAATGG3’ (additional XhoI restric-
tion site shown in bold) primers. The PCR reaction con-
ditions were: 4 min at 94 °C, 5 cycles of 1 min at 94 °C,
1 min at 56 °C, 3 min at 72 °C, 35 cycles of 1 min at 94 °
C, 1 min at 60 °C and 3 min at 72 °C, and final
extension for 10 min at 72 °C. The PCR product was
cloned into the pmirGLO reporter vector (Promega,
Madison, WI, USA) and sequenced (pmirGLO_IGF-1
R_5’ reporter vector). DNA corresponding to the 3’ end
(1327 bp) of 3’UTR of IGF-1R mRNA was cloned with
forward 5’ACTAGAGCTCCACTGAGGCACATCATGG
3’ (added SacI site is shown in bold) and reverse
5’TAAGCTCGAGAGTGATCGTTATGTTCTCGC3’
(added XhoI site is shown in bold) primers. The PCR
Table 1 Basic clinical and biochemical parameters of the elderly
and long-lived study subjects
Elderly Long-lived
n = 52 n = 48
Agea (years) 65.6 ± 3.4 94.2 ± 3.8
BMIa (kg/m2) 28.1 (25.7, 30.10) 25.3 (21.9, 28.6)
Fasting glucosea (mg/dl) 90.2 (81.1, 96.7) 87.5 (83.8, 92.5)
Total cholesterola (mg/dl) 203.2 (177.1, 239.85) 173 (151.8, 203.9)
HDLa (mg/dl) 56 (49.5, 62.3) 51.9 (47, 67.1)
IL-6a (pg/ml) 1.5 (0.8, 2.8) 2.9 (1.4, 4.6)
CRPa (mg/l) 1.9 (1.1, 4.1) 2.4 (1.5, 10.7)
MMSEa 29 (27, 29) 19 (17, 26)
ADLa 6 (6, 6) 6 (4, 6)
a median (25th, 75th percentile)
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conditions and cloning (pmirGLO_IGF-1R_3’ reporter
vector) were the same as above.
DNA corresponding to the 5’ end (1201 bp) of 3’UTR
of FOXO1 mRNA was cloned using forward 5’ACTA-
GAGCTCTGTCAGGCTGAGGGTTAG3’ (added SacI
site is shown in bold, the STOP codon is underlined)
and reverse 5’CTAACTCGAGCTTGATGCTATGCAG-
TACG3’ (added XhoI site is shown in bold) primers,
while for cloning of the 3’ end of this mRNA (1358 bp)
the starters were forward 5’ACTAGAGCTCCTCTAT-
CATCCTCATTTTGG3’ (added SacI site is shown in
bold) and reverse 5’TAAGCTCGAGGGCTGACAA-
GACTTAACTC3’ (added XhoI site is shown in bold).
Both fragments were amplified under the following PCR
conditions: 4 min at 94 °C, 5 cycles of 1 min at 94 °C,
1 min at 56 °C, 3 min at 72 °C, 35 cycles of 1 min at 94 °
C, 1 min at 58 °C and 3 min at 72 °C, and final extension
for 10 min at 72 °C, and then cloned (pmirGLO_-
FOXO1_5’ and pmirGLO_FOXO1_3’ reporter vectors,
respectively) and sequenced.
HEK 293 cells were cultured in a 96-well dish in Dul-
becco Modified Eagle’s medium (Sigma Aldrich, St.
Louis, MO, USA) supplemented with 10% heat-
inactivated fetal bovine serum, without antibiotics, in a
humidified incubator with 5% CO2, at 37 °C. Cells were
transfected at 80% confluency with 0.5 μl lipofectamine
2000 (Invitrogen, Life Technologies, Carlsbad, CA, USA)
in 50 μl Opti-MEM I medium (Gibco, Life Technologies,
Grand Island, NY, USA) without serum, according to the
lipofectamine manufacturer’s protocol. Eighty ng of
pmirGLO with or without cloned 3’UTR-encoding DNA
and 5 pmol of pre-miRNA (pre-miR-96, pre-miR-182 or
pre-miR miRNA Precursor Negative Control #2 for IGF-
1R, and pre-miR-145, pre-miR-132 or pre-miR miRNA
Precursor Negative Control #2 for FOXO1, Ambion, Life
Technologies, Carlsbad, CA USA) were used. Cells were
then cultured for 24 h without changing medium,
washed with phosphate-buffered saline, and lysed for
15 min with 20 μl Passive Lysis Buffer (Promega, Madi-
son, WI, USA) on a rocking platform. The luminescence
was assessed in the Centro XS3 LB 960 luminometer
(Berthold Technologies, Bad Wilbad, Germany). The lu-
minescence of firefly luciferase substrate was normalized
against that of Renilla luciferase substrate. Each experi-
ment was repeated 15 times.
Statistical analysis
Statistical calculations were performed using STATIS-
TICA 10. To assess normality of the distribution, the
Shapiro-Wilk test was used. Since the distribution of the
expressions of the genes of interest and of miRNAs was
not normal, statistical analyses were performed with the
Kruskal-Wallis test. The effect of low-dose acetylsalicylic
acid on gene and miRNA expression was analyzed with
U Mann–Whitney test. The effect of miRNA interaction
with the respective mRNA on the reporter protein activ-
ity was analyzed by the two-sided Student’s t test.
Correlation between the mRNA and the studied miRNA
expressions was calculated by the Spearman’s rank
correlation coefficient. For all tests the level of signifi-
cance was established at 0.05.
Results
Expression of the IGF-1R, FOXO1, and FOXO3a mRNA in
PBMC of young, elderly, and long-lived individuals
We first established whether age affected the mean Cp
values for the ACTB control gene. We found that they
did not differ between age groups (Y: 20.4 ± 0.8, E: 21 ±
1.9, L: 20.1 ± 0.8) and concluded that ACTB can be used
as the internal control in assessing the expression of
genes of interest. The median (25th, 75th percentile) ex-
pression of IGF-1R expressed in arbitrary units was not
statistically different in men and women or in low-dose
acetylsalicylic acid users and non-users, and further ana-
lyses were performed for all study subjects together. The
median expression of IGF-1R was 1.04 (0.85, 1.34), 0.62
(0.48, 0.91), and 0.57 (0.43, 0.74) in the Y, E, and L
groups, respectively, and significantly decreased with age
(p < 0.00001). The differences between the Y and E, as
well as Y and L groups were significant (p = 0.000006
and p < 0.000001, respectively), while the difference be-
tween the E and L groups was not.
The median expression of FOXO1 expressed in arbi-
trary units was similar in men and in women, as well as
in low-dose acetylsalicylic acid users and non-users, and
all study subjects were pooled for further analyses. The
median expression of this gene was 1.02 (0.8, 1.37), 0.78
(0.49, 1.12), and 0.61 (0.47, 0.78) in the Y, E, and L
groups, respectively, and significantly decreased with age
(p < 0.000001). The differences were significant for the Y
vs. E and Y vs. L groups (p = 0.0013 and p < 0.000001, re-
spectively), while for the E vs. L groups it was not
significant.
Finally, the median expression of FOXO3a was not as-
sociated with gender nor with low-dose acetylsalicylic
acid use. Its median expression was 0.95 (0.79, 1.17),
0.87 (0.66, 1.14), and 1.0 (0.77, 1.2) in the Y, E, and L
groups, respectively, and was not dependent on age.
Interaction of miRNAs with the IGF-1R mRNA and FOXO1
mRNA
Since the interaction between the IGF-1R mRNA vs.
miR-99a or miR-145, as well as the FOXO1 mRNA vs.
miR-9, miR-96, or miR-182 has been previously shown
by other authors [45–48], we conducted functional stud-
ies only for the IGF-1R mRNA vs. miR-96 and miR-182,
and for the FOXO1 mRNA vs. miR-145 and miR-132.
Budzinska et al. BMC Geriatrics  (2016) 16:200 Page 4 of 9
3’UTR of IGF-1R mRNA contains two putative miR-96
and two putative miR-182 binding sites; therefore, each
site was analyzed separately. The mean luminescence in-
duced by firefly luciferase expressed from the reporter
vectors pmirGLO_IGF-1R_5’ or pmirGLO_IGF-1R_3’ in
the presence of negative control miRNA was normalized
to 100%. Co-transfection of pmirGLO_IGF-1R_5’ or
pmirGLO_IGF-1R_3’ with pre-miR-96 (Fig. 1a, b) de-
creased luminescence on average by 31% (p = 0.01) and
17.2% (p = 0.05), respectively, showing that miR-96 inter-
acts with both fragments of the 3’UTR of IGF-1R mRNA
and decreases translation of the reporter protein. Co-
transfection with pre-miR-182 showed that only the
binding site located within the 5’ fragment of 3’UTR of
IGF-1R mRNA (Fig. 1c) was functional since the lumi-
nescence induced by firefly luciferase expressed from the
pmirGLO_IGF-1R_5’ vector decreased by 29.5% (p =
0.0005). In contrast, there was no interaction between
miR-182 and its second putative binding site (Fig. 1d).
Similarly, the mean luminescence induced by firefly lu-
ciferase expressed from the reporter vectors pmirGLO_-
FOXO1_5’ or pmirGLO_FOXO1_3’ in the presence of
negative control miRNA was normalized to 100%. Co-
transfection of pmirGLO_FOXO1_5’ and pre-miR-145
(Fig. 2a) decreased luminescence by 39.3% (p <
0.000001). Co-transfection of pmirGLO_FOXO1_3’ with
pre-miR-132 (Fig. 2b) decreased luminescence by 42.4%
(p < 0.000001) suggesting that in silico-designated single
binding sites for these miRNAs were functional.
Age-dependent changes of expression of miRNAs in
PBMC
The median expression of any of the tested miRNAs did
not differ between men and women, or between low-
ba
dc
Fig. 1 miR-96 and miR-182 interact with the 3’UTR of IGF-1R mRNA. HEK 293 cells were co-transfected with the pmirGLO reporter vector and
miRNA precursors. The mean relative luminescence induced by firefly luciferase expressed from the reporter vectors containing cloned DNA
corresponding to the 3’UTR fragments, in the presence of negative control miRNA, was normalized to 100%. miR-96 interacts with two (a, b), and
miR-182 with one out of two in silico indicated binding sites (c, d). pmirGLO: “empty” reporter vector; pmirGLO_IGF-1R_5’: reporter vector
containing DNA corresponding to the 5’ end of 3’UTR of IGF-1R mRNA; pmirGLO_IGF-1R_3’: reporter vector containing DNA corresponding to the
3’ end of 3’UTR of IGF-1R mRNA; pre-miR-neg, pre-miR-96, pre-miR-182: miRNA precursors
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dose acetylsalicylic acid users and non-users, and all
study subjects were analyzed together. The median ex-
pression of miR-96 increased with age (p = 0.002 for the
whole tested group, Y vs. E: p = 0.009, Y vs. L: p = 0.006),
as did the median expression of miR-145 (p = 0.024 for
the whole group, E vs. L: p = 0.029) and of miR-9 (p =
0.026 for the whole group, Y vs. L: p = 0.021). In contrast,
the expression of miR-99a decreased with age (p = 0.037
for the whole group, Y vs. E: p = 0.038). The expression of
miR-132 and miR-182 remained stable (Table 2).
There was a weak, but significant negative correlation
between the expression of FOXO1 and expression of
miR-96 (Rs = −0.202, p = 0.017).
Discussion
In this work we showed that the expression of key com-
ponents of the IGF-1 pathway, the IGF1-R and FOXO1
genes, decreases with age, while the median expression
of FOXO3a remains stable in PBMC of aging humans.
The increased function of the IGF-1 pathway has been
shown to enhance proliferation of T lymphocytes, pro-
mote their survival and stimulate the production of
TNF-α and IL-8, stimulate B lymphocyte proliferation
and differentiation and enhance immunoglobulin pro-
duction, as well as to enhance natural killer cell activity,
thus exerting a pro-inflammatory effect [49–52]. On the
other hand, by stimulation of IL-10 expression and in-
hibition of Th-1-mediated immune responses in activated
T lymphocytes, the increased function of this pathway
exerts anti-inflammatory actions [53]. Upregulation of
FOXO1 increases the number of naive T and B lympho-
cytes, accompanies T and cell maturation and supports
their homing to lymph nodes [54–56]. It maintains their
quiescence, and contributes to immune tolerance [55, 57].
Therefore, an age-associated decrease of expression of
IGF-1R and FOXO1 in these cells likely contributes to
altered antibody production and natural killer function,
as well as to alterations and imbalance in the production
a b
Fig. 2 miR-145 and miR-132 interact with the 3’UTR of FOXO1 mRNA. HEK 293 cells were co-transfected with the pmirGLO reporter vector and
miRNA precursors. The mean relative luminescence induced by firefly luciferase expressed from the reporter vectors containing cloned 3’UTR
fragments in the presence of negative control miRNA was normalized to 100%. Both miR-145 (a) and miR-132 (b) interact with in silico indicated
binding sites. pmirGLO: “empty” reporter vector; pmirGLO_FOXO1_5’: reporter vector containing DNA corresponding to the 5’ end of 3’UTR of
FOXO1 mRNA; pmirGLO_FOXO1_3’: reporter vector containing DNA corresponding to the 3’ end of 3’UTR of FOXO1 mRNA; pre-miR-neg,
pre-miR-145, pre-miR-132: miRNA precursors
Table 2 Age-related changes of the expression of the selected miRNAs in human peripheral blood mononuclear cells
Expression arbitrary units [median value (25th, 75th percentile)] P-value
miRNA Ya Eb Lc Y vs. E E vs. L Y vs. L
miR-9 0.39 (0.16, 0.82) 0.54 (0.16, 1.13) 0.96 (0.27, 1.40) p = 766 p = 0.381 p = 0.021
miR-96 0.29 (0.10, 0.53) 0.75 (0.22, 2.06) 0.74 (0.23, 2.52) p = 0.009 p = 1 p = 0.006
miR-99a 2.42 (1.16, 4.83) 1.23 (0.53, 2.59) 1.50 (0.83, 3.41) p = 0.038 p = 1 p = 0.265
miR-132 0.21 (0.08, 0.41) 0.21 (0.11, 0.41) 0.25 (0.12, 0.50) p = 1 p = 1 p = 1
miR-145 0.14 (0.07, 0.47) 0.13 (0.06, 0.34) 0.27 (0.13, 0.57) p = 1 p = 0.029 p = 0.104
miR-182 0.18 (0.10, 0.47) 0.21 (0.06, 1.02) 0.23 (0.09, 1.55) p = 1 p = 0.752 p = 0.292
a: young (Y), b: elderly (E), c long-lived (L) individuals
Significant p-values are shown in bold
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of pro-inflammatory and anti-inflammatory agents
termed inflammaging, a phenomenon increasing the risk
of developing aging-related diseases [58, 59]. Notably,
the effects of the downregulation of IGF-1R and FOXO1
might be additive on some immune functions but op-
posite on others.
It should be noted, however, that the decrease of
IGF-1R and FOXO1 expression was also observed in
PBMC of long-lived individuals who had never been
diagnosed with any aging-related disease. This sug-
gests that in these individuals most possibly genetic-
ally predisposed to longevity, such a decrease either is
not very harmful to the immune system, or is compen-
sated by other factors. For example, the effect of
overproduction of pro-inflammatory agents can be
overcome by the increased production of anti-
inflammatory factors (anti-inflammaging) [60, 61].
Nevertheless, it is highly relevant to establish whether
downregulation of these genes in PBMC of persons
not predisposed to longevity or subjected to the nega-
tive influences of environmental factors is also of
minor importance or, on the contrary, contributes to
their increased morbidity and mortality.
Remarkably, the expression of FOXO3a in PBMC of
our study participants was not affected by age. FOXO3a
has been shown to play a pivotal role in maintaining the
hematopoietic stem cell, T cell progenitor, and memory
T cell pools, in B cell differentiation and persistence of
memory B cells, and in promoting survival of natural
killer cells [62]. The fact that our results show its expres-
sion to be similar independently of age, suggests that its
sustained function might be crucial for the maintenance
of the immune system function during aging.
In this work we also attempted to elucidate the mech-
anisms underlying the observed age-dependent differ-
ences in the expression of IGF-1R and FOXO1.
Molecular mechanisms affecting gene/protein expression
are multiple and include those that influence the rate of
transcription, mRNA maturation, transport and stability,
the rate of translation, etc. miRNAs activity seems to be
one of the important mechanisms affecting gene expres-
sion in the context of aging, because the change of miR-
NAs expression is one of the features of aging-associated
epigenetic drift [6]. We showed that the median expres-
sion of miR-96 and miR-145, both functionally interact-
ing with the IGF-1R and FOXO1 mRNAs, as well as of
miR-9 interacting with the FOXO1 mRNA, was higher
in PBMC of aging humans than of young study subjects.
We therefore propose that such an increase might be
among the factors that contribute to the decreased
expression of IGF-1R and FOXO1 in these cells. In the
case of other tested miRNAs, since their expression did
not change with age, we conclude that they do not
participate in this phenomenon.
This work has some limitations. We studied unfractio-
nated blood mononuclear cells, conscious that the gene
expression changes and some features of epigenetic drift
might be cell type-specific. Since the percentage of im-
mune cell subtypes changes with age also in apparently
healthy humans, the described changes in expression
might in part reflect such a quantitative change. In
addition, analysis at the protein level would strengthen
the validity of our results. However, even though blood
is the only biological material easily obtainable from liv-
ing human donors, the amount of it that we were
allowed to collect from the elderly and long-lived indi-
viduals was insufficient to carry out efficient fraction-
ation and subsequent analyses. In addition, fractionation
followed by cell culturing could increase the number of
cells, but we decided not to do so because this could
affect the expression of miRNAs and genes. Another
reason for studying changes in PBMC was that aging
studies involving living humans are commonly carried
out on blood cells and using PBMC allowed the com-
parison of our results with other data, both published
[63–65] and yet to be published.
Conclusions
To sum up, in this work we showed that aging is associ-
ated with a decreased expression of IGF-1R and FOXO1
in human PBMC and that this in part can be the result
of epigenetic drift. We also show that the sustained
expression of FOXO3a might be important for the main-
tenance of the immune system function in aging
humans.
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